Videos

Imlunestrant Shows Promise for Patients With ESR1-Mutated Advanced Breast Cancer
Dr Erica Mayer discusses the positive results of the EMBER-3 trial, and the impact that imlunestrant will have on the treatment of patients with advanced breast cancer Watch Video ›

Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma. Watch Video ›

Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma. Watch Video ›

Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma. Watch Video ›

Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC. Watch Video ›

Finding Your Strength Through Knowledge
Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, shares topics presented at the 2021 San Antonio Breast Cancer Symposium to help empower patients with breast cancer. Watch Video ›

Key Abstracts from ASCO 2021 in NSCLC
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC. Watch Video ›

Combination Therapies and New Molecular Targets—Presentations from AACR 2021
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents. Watch Video ›

Practice-Changing Data in NSCLC from ASCO 2021
Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC. Watch Video ›

Exciting New Data Presented on NSCLC at AACR 2021
Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC. Watch Video ›

Page 3 of 6